Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...
A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.
RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback